Global Leading Market Research Publisher QYResearch announces the release of its latest report *”Vesicoureteral Reflux Treatment – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*. Vesicoureteral reflux (VUR) is a condition where urine flows backward from the bladder into one or both ureters and sometimes up into the kidneys. This can potentially lead to urinary tract infections (UTIs) and kidney damage (renal scarring, hypertension, chronic kidney disease, end-stage renal disease). VUR affects approximately 1-2% of all children and 30-50% of children presenting with febrile UTIs, with the highest prevalence in infants and young children (under 2 years). The treatment approach for vesicoureteral reflux may vary based on the severity of the condition (graded I-V) and the associated risks (breakthrough UTIs, renal scarring). Unlike asymptomatic VUR (observation only), high-grade VUR (III-V) with breakthrough infections requires active intervention. This deep-dive analysis incorporates QYResearch’s latest forecast, supplemented by 2025–2026 market data, technology trends, and a comparative framework across drug therapy (antibiotic prophylaxis), surgical treatment (ureteral reimplantation), and gel injections (endoscopic injection of bulking agents), as well as across hospital, ambulatory surgery center, and other settings.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5985800/vesicoureteral-reflux-treatment
Market Sizing & Pharmaceutical Context (Updated with 2026 Interim Data)
The global market for Vesicoureteral Reflux Treatment (including drug therapy, surgical devices, and endoscopic injection materials) was estimated to be worth approximately US$ 350-450 million in 2025 and is projected to reach US$ 500-650 million by 2032, growing at a CAGR of 5-6% from 2026 to 2032. The global pharmaceutical market was valued at approximately US$ 1,475 billion in 2022, growing at a CAGR of 5% through 2028. The biologics segment reached US$ 381 billion in 2022, while the chemical drug market increased from US$ 1,005 billion in 2018 to US$ 1,094 billion in 2022. Key drivers for the broader pharmaceutical market—increasing healthcare demand, technological advancements, rising chronic disease prevalence, and increased R&D funding—also underpin the VUR treatment market. Notably, the surgical treatment segment captured 50% of market value (ureteral reimplantation, gold standard for high-grade VUR), while gel injections (endoscopic injection) held 30% (fastest-growing at 7% CAGR, minimally invasive), and drug therapy (antibiotic prophylaxis) held 20% (declining due to antibiotic resistance concerns and new guidelines). The hospital segment dominated with 70% share (surgical procedures, inpatient care), while ambulatory surgery center held 25% (fastest-growing at 6% CAGR, endoscopic injections), and others (office-based procedures) held 5%.
Product Definition & Functional Differentiation
Vesicoureteral reflux (VUR) treatment refers to interventions that prevent retrograde urine flow from the bladder into the ureters and kidneys, reducing the risk of UTIs and renal scarring. Unlike asymptomatic VUR (observation only, resolves spontaneously in many children), high-grade VUR (III-V) with breakthrough infections requires active intervention.
VUR Grading & Treatment Algorithm (2026):
| Grade | Description | Spontaneous Resolution Rate | Treatment Approach |
|---|---|---|---|
| I | Ureter only (no dilation) | 80-85% | Observation or antibiotic prophylaxis |
| II | Ureter + renal pelvis (no calyceal dilation) | 70-80% | Observation or antibiotic prophylaxis |
| III | Mild to moderate ureteral and calyceal dilation | 50-60% | Antibiotic prophylaxis or endoscopic injection |
| IV | Moderate ureteral tortuosity and calyceal dilation (blunting) | 30-40% | Endoscopic injection or ureteral reimplantation |
| V | Severe ureteral tortuosity and calyceal dilation (loss of papillary impression) | <20% | Ureteral reimplantation (open or robotic) |
VUR Treatment Options (2026):
| Treatment | Mechanism | Success Rate | Invasiveness | Recovery Time | Cost | Suitable for Grades |
|---|---|---|---|---|---|---|
| Drug Therapy (Antibiotic Prophylaxis) | Continuous low-dose antibiotics (trimethoprim-sulfamethoxazole, nitrofurantoin, cephalexin) prevent UTIs | 70-80% (prevents UTIs, does not correct reflux) | Non-invasive (oral) | N/A | Low ($100-500/year) | I-IV (mild to moderate) |
| Endoscopic Injection (Gel Injection) | Dextranomer/hyaluronic acid copolymer (Deflux) injected beneath the ureteral orifice (subureteral) to create a bulge, preventing reflux | 70-85% (after 1 injection) | Minimally invasive (cystoscopy, 15-30 min) | Same day (outpatient) | Moderate ($5,000-10,000) | II-IV (especially III-IV) |
| Surgical Treatment (Ureteral Reimplantation) | Open, laparoscopic, or robotic-assisted reimplantation of ureter into bladder (Politano-Leadbetter, Cohen, Glenn-Anderson) | 95-98% | Invasive (open or laparoscopic) | 1-3 days hospital, 2-4 weeks recovery | High ($15,000-30,000+) | IV-V (severe), failed endoscopic injection |
Industry Segmentation & Recent Adoption Patterns
By Treatment Type:
- Surgical Treatment (Ureteral Reimplantation) (50% market value share, mature at 4% CAGR) – Gold standard for high-grade VUR (IV-V), failed endoscopic injection. Open, laparoscopic, and robotic-assisted approaches.
- Gel Injections (Endoscopic Injection) (30% share, fastest-growing at 7% CAGR) – Minimally invasive, outpatient procedure, preferred for moderate VUR (III-IV). Dextranomer/hyaluronic acid (Deflux) is the most widely used bulking agent.
- Drug Therapy (Antibiotic Prophylaxis) (20% share, declining) – Continuous low-dose antibiotics. Declining due to antibiotic resistance concerns (increasing UTIs caused by resistant organisms), new guidelines (American Urological Association, European Association of Urology) recommend observation or early intervention.
By End-User:
- Hospital (pediatric urology departments, inpatient surgical units) – 70% of market, largest segment. Ureteral reimplantation (open, laparoscopic, robotic) requires hospital admission.
- Ambulatory Surgery Center (ASC) (outpatient surgical centers) – 25% share, fastest-growing at 6% CAGR. Endoscopic injections (Deflux) are typically performed in ASCs.
- Others (office-based procedures, clinics) – 5% share.
Key Players & Competitive Dynamics (2026 Update)
Leading vendors include: Johnson & Johnson Services (USA, Dextranomer/hyaluronic acid copolymer, Deflux), Medtronic PLC (Ireland, surgical devices), Fresenius SE & Co. KGaA (Germany), Abbott Laboratories (USA), Bayer AG (Germany), Cook Group Incorporated (USA, urological devices), GE Healthcare (USA, diagnostic imaging), Boston Scientific Corp. (USA, urological devices), Zimmer Biomet Holdings (USA), Novartis AG (Switzerland). Johnson & Johnson (Deflux) dominates the endoscopic injection market (dextranomer/hyaluronic acid copolymer) for VUR. Boston Scientific and Cook Medical provide ureteral reimplantation surgical instruments (laparoscopic, robotic). Medtronic and Abbott focus on antibiotic prophylaxis (oral antibiotics) and diagnostic imaging. In 2026, Johnson & Johnson (Deflux) remains the only FDA-approved bulking agent for VUR (dextranomer/hyaluronic acid copolymer). Boston Scientific launched “Boston Scientific VUR Surgical Kit” for laparoscopic ureteral reimplantation (reusable instruments, disposable trocars). Cook Medical introduced “Cook Medical Ureteral Reimplantation Set” for open and laparoscopic procedures (sutures, stents, catheters). Medtronic expanded antibiotic prophylaxis portfolio (trimethoprim-sulfamethoxazole, nitrofurantoin, cephalexin) for pediatric VUR.
Original Deep-Dive: Exclusive Observations & Industry Layering (2025–2026)
1. Discrete Treatment Algorithm vs. One-Size-Fits-All
| Grade | Spontaneous Resolution | Treatment Recommendation (AUA/EUA 2025) | Market Impact |
|---|---|---|---|
| I-II | High (80-85%) | Observation (no antibiotics) | Declining antibiotic use |
| III | Moderate (50-60%) | Antibiotic prophylaxis or endoscopic injection | Growing endoscopic injection |
| IV-V | Low (20-40%) | Endoscopic injection or ureteral reimplantation | Surgical treatment dominant |
2. Technical Pain Points & Recent Breakthroughs (2025–2026)
- Antibiotic resistance (prophylaxis) : Continuous low-dose antibiotics increase risk of resistant UTIs. New guidelines (AUA, EAU, 2025) recommend observation for low-grade VUR (I-II) and early endoscopic injection for moderate VUR (III-IV) to reduce antibiotic exposure.
- Deflux durability (endoscopic injection) : Dextranomer/hyaluronic acid copolymer may migrate or degrade over time (5-10% recurrence). New next-generation bulking agents (polyacrylate polyalcohol copolymer, Vantris) (in development, not yet FDA-approved) with improved durability.
- Minimally invasive ureteral reimplantation (robotic) : Open ureteral reimplantation has longer recovery (2-4 weeks). New robotic-assisted laparoscopic ureteral reimplantation (RALUR) (Boston Scientific, Intuitive Surgical, 2025) reduces hospital stay (1-2 days vs. 3-5 days) and recovery time (1-2 weeks vs. 2-4 weeks).
- Imaging for VUR diagnosis (voiding cystourethrogram, VCUG) : VCUG requires catheterization and radiation exposure (pediatric concern). New contrast-enhanced voiding urosonography (ceVUS) (ultrasound, no radiation) and magnetic resonance urography (MRU) (no radiation) are gaining acceptance.
3. Real-World User Cases (2025–2026)
Case A – Endoscopic Injection (Grade III VUR) : Boston Children’s Hospital (USA) performed Deflux endoscopic injection for 4-year-old with grade III VUR and breakthrough UTIs (2025). Results: (1) outpatient procedure (15 minutes); (2) same-day discharge; (3) 85% success rate (no reflux on follow-up VCUG); (4) no antibiotics post-procedure. “Endoscopic injection is the preferred treatment for moderate VUR.”
Case B – Ureteral Reimplantation (Grade V VUR) : Cincinnati Children’s Hospital (USA) performed robotic-assisted laparoscopic ureteral reimplantation (RALUR) for 6-year-old with grade V VUR (2026). Results: (1) 98% success rate; (2) 2-day hospital stay; (3) 2-week recovery; (4) no breakthrough UTIs at 1-year follow-up. “Robotic ureteral reimplantation is the gold standard for high-grade VUR.”
Strategic Implications for Stakeholders
For pediatric urologists and hospital administrators, VUR treatment selection depends on: (1) VUR grade (I-V), (2) patient age (spontaneous resolution higher in younger children), (3) breakthrough UTIs (frequency, severity), (4) renal scarring (DMSA scan), (5) parental preference, (6) antibiotic resistance concerns, (7) cost (antibiotics vs. endoscopic injection vs. surgery), (8) facility capability (ASC vs. hospital). For manufacturers, growth opportunities include: (1) next-generation bulking agents (improved durability), (2) robotic-assisted ureteral reimplantation (minimally invasive), (3) antibiotic stewardship (reducing prophylaxis), (4) non-ionizing imaging (ceVUS, MRU), (5) pediatric-specific devices (smaller instruments), (6) outpatient surgical kits (ASC-friendly), (7) patient registries (long-term outcomes).
Conclusion
The vesicoureteral reflux treatment market is growing at 5-6% CAGR, driven by endoscopic injection adoption (minimally invasive), robotic ureteral reimplantation, and antibiotic stewardship (reducing prophylaxis). Surgical treatment (50% share) dominates, with gel injections (7% CAGR) fastest-growing. Hospital (70% share) is the largest end-user, with ambulatory surgery centers (6% CAGR) fastest-growing. Johnson & Johnson (Deflux), Boston Scientific, Cook Medical, and Medtronic lead the market. As QYResearch’s forthcoming report details, the convergence of next-generation bulking agents, robotic-assisted ureteral reimplantation (minimally invasive) , antibiotic stewardship (reducing prophylaxis) , non-ionizing imaging (ceVUS, MRU) , and ASC-based endoscopic injections will continue expanding the category as the standard of care for VUR management.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
